Basilea Pharmaceutica (BPMUF) News Today $52.83 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Basilea Pharmaceutica (OTCMKTS:BPMUF) Hits New 12-Month High - What's Next?Basilea Pharmaceutica (OTCMKTS:BPMUF) Hits New 12-Month High - Here's WhyOctober 24, 2024 | marketbeat.comStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this yearOctober 10, 2024 | markets.businessinsider.comBasilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasisSeptember 24, 2024 | markets.businessinsider.comBasilea Pharmaceutica (BSLN) Gets a Buy from Kepler CapitalSeptember 22, 2024 | markets.businessinsider.comBasilea Reaches Deal With BARDA To Develop Novel Antifungals And Antibacterials; Raises FY OutlookSeptember 19, 2024 | markets.businessinsider.comStrong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to BasileaSeptember 6, 2024 | markets.businessinsider.comBasilea Receives $25 Mln Milestone Payment Following Strong Cresemba Sales Performance In EuropeSeptember 6, 2024 | markets.businessinsider.comHC Wainwright Weighs in on Basilea Pharmaceutica AG's FY2024 Earnings (OTCMKTS:BPMUF)Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - Stock analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of Basilea Pharmaceutica in a research report issued to clients and investors on Wednesday, August 28th. HC Wainwright analyst R. Selvaraju now expeAugust 30, 2024 | marketbeat.comBasilea Pharmaceutica AG (BPMUF)August 29, 2024 | finance.yahoo.comShort Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Declines By 57.0%Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 31,100 shares, a decline of 57.0% from the July 31st total of 72,300 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.August 28, 2024 | marketbeat.comHalf Year 2024 Basilea Pharmaceutica AG Allschwil Earnings Call TranscriptAugust 16, 2024 | gurufocus.comBasilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidanceAugust 13, 2024 | markets.businessinsider.comBasilea Pharma H1 Results Down; Lifts FY24 GuidanceAugust 13, 2024 | markets.businessinsider.comBasilea Pharmaceutica (BSLN) Receives a Buy from Kepler CapitalAugust 3, 2024 | markets.businessinsider.comStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaMay 16, 2024 | finance.yahoo.comBPMUF Basilea Pharmaceutica AGMay 4, 2024 | seekingalpha.comBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024May 3, 2024 | finance.yahoo.comBasilea shareholders approve all proposals of the board of directors at the annual general meetingApril 24, 2024 | finance.yahoo.comBasilea Pharmaceutica AG (0QNA.L)April 24, 2024 | finance.yahoo.comBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsApril 9, 2024 | finance.yahoo.comUPDATE 2-US FDA approves Basilea Pharmaceutica's antibioticApril 4, 2024 | msn.comEuropean stocks rise ahead of inflation data; Basilea shinesApril 4, 2024 | msn.comBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsApril 4, 2024 | finance.yahoo.comUS FDA approves Basilea Pharmaceutica's antibioticApril 3, 2024 | reuters.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaMarch 11, 2024 | finance.yahoo.comBasilea Pharmaceutica AG Expected to Earn FY2024 Earnings of $1.85 Per Share (OTCMKTS:BPMUF)Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - Equities research analysts at Edison Inv. Res dropped their FY2024 earnings per share estimates for Basilea Pharmaceutica in a research report issued on Tuesday, February 20th. Edison Inv. Res analyst S. Romanoff now anticipates that the coFebruary 22, 2024 | marketbeat.comBasilea Pharmaceutica AG (BSLN)February 21, 2024 | investing.comBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioFebruary 13, 2024 | finance.yahoo.comCresemba® sales in Latin America trigger first sales milestone payment to BasileaJanuary 19, 2024 | finance.yahoo.comBasilea To Buy Preclinical Antibiotics Program From SpexisJanuary 15, 2024 | markets.businessinsider.comBasilea announces acquisition of preclinical antibiotics program from SpexisJanuary 15, 2024 | finance.yahoo.comBasilea provides portfolio status updateJanuary 5, 2024 | finance.yahoo.comBasilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured LoanDecember 20, 2023 | markets.businessinsider.comBasilea announces accelerated loan repaymentDecember 20, 2023 | finance.yahoo.comBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisDecember 11, 2023 | finance.yahoo.comBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsDecember 4, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearNovember 20, 2023 | finance.yahoo.comPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalNovember 13, 2023 | msn.comBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalNovember 13, 2023 | finance.yahoo.comBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentOctober 31, 2023 | finance.yahoo.comBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infectionsOctober 19, 2023 | finance.yahoo.comBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023October 17, 2023 | finance.yahoo.comBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiproleOctober 2, 2023 | finance.yahoo.comBasilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremiaSeptember 28, 2023 | finance.yahoo.comBasilea reports strong revenue and profit growth in first half-year 2023August 15, 2023 | finance.yahoo.comBasilea Pharma Submits NDA For Antibiotic CeftobiproleAugust 4, 2023 | markets.businessinsider.comBasilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiproleAugust 4, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to BasileaJune 8, 2023 | finance.yahoo.comBasilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiproleApril 18, 2023 | finance.yahoo.comBasilea Pharmaceutica Posts FY ProfitFebruary 14, 2023 | markets.businessinsider.com Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. BPMUF Media Mentions By Week BPMUF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMUF News Sentiment▼0.000.45▲Average Medical News Sentiment BPMUF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMUF Articles This Week▼00▲BPMUF Articles Average Week Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMPH News Today CGON News Today TWST News Today ARWR News Today SRRK News Today ACAD News Today HRMY News Today VERA News Today LBPH News Today IDYA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BPMUF) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Basilea Pharmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPMUF Stock Alerts